Drug intelligence / Profile preview

D012 + D326 + D337

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

D012 + D326 + D337 is an oral investigational fixed-dose combination consisting of three experimental compounds, administered as three tablets together under fasting conditions in pharmacokinetic and drug-drug interaction studies. It has been studied as part of CKD-386 F2 formulations by Chong Kun Dang Pharmaceutical and is used in early-phase clinical research, with no identified mechanism of action or indications disclosed in public resources.

Brand names: CKD-386 F2CKD386 F2CKD 386 F2
Other names: CKD-386 F2CKD386 F2CKD 386 F2

Beyond the preview

Go deeper on D012 + D326 + D337.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D012 + D326 + D337.

Explore the full profile